Form 8-K Corvus Pharmaceuticals, For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Corvus Pharmaceuticals (CRVS) PT Lowered to $7 at Oppenheimer
March 20, 2024 4:38 AM EDTOppenheimer analyst Jeff Jones lowered the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $7.00 (from $8.00) while maintaining a Outperform rating.
The analyst comments "On Tuesday CRVS announced 4Q and full-year results, highlighting a somewhat narrowed plan for lead candidate soquelitinib. Management is... More
